Showing results (6111-6120 of 10,388) with videos related to

Sort By:
Pageof 1,039
Vaccines|October 28, 2025
Serological Response After the Fourth Dose of COVID-19 Vaccine in Highly Immunosuppressed PatientsAbelardo Claudio Fernández Chávez, Paula Navarro López, Ana De Andrés Martín, et al.
Vaccines|October 28, 2025
Reactogenicity of an Inactivated, Split-Virion Quadrivalent Influenza Vaccine in Infants and Children Aged ≥6 Months to <9 YearsTerry Nolan, Frank R Albano, Janine Oberije, et al.
Vaccines|October 28, 2025
Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome VirusChaitawat Sirisereewan, John J Byrne, Lanre Sulaiman, et al.
Vaccines|October 28, 2025
Safety Profile of the 4CMenB (Bexsero®) Vaccine: A Systematic Review and Meta-Analysis of Adverse Events in Clinical TrialsAna Belén García Flores, Rafael Ruiz-Montero, María Ángeles Onieva-García, et al.
Vaccines|October 28, 2025
Immunoproteomic Screening of Candidate Antigens for the Preliminary Development of a Novel Multi-Component and Multi-Epitope Vaccine Against Streptococcus suis InfectionYue Zhang, Caiying Li, Yutong Feng, et al.
Vaccines|October 28, 2025
The Potential Public Health Impact of the mRNA-Based Respiratory Syncytial Virus Vaccine, mRNA-1345, Under Extended Vaccination Campaigns Among Older Adults in the United Kingdom: A Modelling StudyMariia Dronova, Anna Tytuła, Zuzanna Janusz, et al.
Vaccines|October 28, 2025
Next-Generation Sequencing Reveals Field Strain Dynamics and PRRSV-2 Clearance in Gilts When Using Tylvalosin During MLV VaccinationWeixin Wu, Xiang Gao, Junfeng Gao, et al.
Vaccines|October 28, 2025
Japanese Encephalitis Vaccine in Low- and Middle-Income Countries (LMICs): A Narrative Review of Efficacy, Effectiveness, Safety, Cost, and PolicyEufrasia Ine Pilihanto, Btari Kalisha Nyratri, Muhammad Dafrizal Firdaus, et al.
Vaccines|October 28, 2025
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192Tosin Omole, Enrique Pelayo, Aaron S Weinberg, et al.
Vaccines|October 28, 2025
A Phase III Clinical Trial of Immunogenicity and Safety of Meningococcal A and C Polysaccharide Conjugate Vaccine in Infants Aged 3-5 MonthsLiwei Shi, Zhe Zhang, Yuqing Liu, et al.
Pageof 1,039